GlassScriptPhysician profile
Vivien Doan Pham
NPI 1427253012
$2,256.00
in general payments reported to CMS, 2019-2025
14 companies · $464 in 2025
The $464 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $42.65 · 2021: $191 · 2022: $314 · 2023: $279 · 2024: $371 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $375.59 | 2019-2023 | Bexsero, Pediarix |
| Pfizer INC. | $284.94 | 2019-2024 | |
| Corium, LLC | $284.61 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $276.98 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $227.09 | 2019-2024 | |
| Tris Pharma INC | $172.59 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $155.72 | 2024-2025 | |
| Cranial Technologies, INC | $151.47 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $143.79 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $75.62 | 2022-2024 | Gardasil 9, Vaxneuvance, Proquad |
| Sanofi Pasteur INC. | $47.75 | 2021-2023 | |
| Photonicare INC | $25.02 | 2025 | Otosight Middle Ear Scope |
| Takeda Pharmaceuticals U.S.A., INC. | $21.60 | 2022 | |
| Adlon Therapeutics L.P. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivien Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.